Cost-effectiveness analysis of two treatment strategies for chronic hepatitis C before and after access to direct-acting antivirals in Spain

Chen, 2006, The natural history of hepatitis C virus (HCV) infection, Int J Med Sci, 3, 47, 10.7150/ijms.3.47 Lavanchy, 2009, The global burden of hepatitis C, Liver Int, 29 Suppl 1, 74, 10.1111/j.1478-3231.2008.01934.x Younossi, 2014, Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients, J Hepatol, 60, 530, 10.1016/j.jhep.2013.11.009 Razavi, 2014, The present and future disease burden of hepatitis virus (HCV) infection with today's treatment paradigm, J Viral Hepat, 21 Suppl 1, 34, 10.1111/jvh.12248 Stanaway, 2016, The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013, Lancet, 388, 1081, 10.1016/S0140-6736(16)30579-7 Butt, 2009, Effect of hepatitis C virus and its treatment on survival, Hepatology, 50, 387, 10.1002/hep.23000 Van der Meer, 2012, Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis, JAMA, 308, 2584, 10.1001/jama.2012.144878 Suwanthawornkul, 2015, Efficacy of second generation direct-acting antiviral agents for treatment naïve hepatitis C genotype 1: a systematic review and network meta-analysis, PLoS One, 10, e0145953, 10.1371/journal.pone.0145953 Pérez-Pitarch, 2016, A model-based meta-analysis of sofosbuvir-based treatments in chronic hepatitis C patients, Int J Antimicrob Agents, 47, 184, 10.1016/j.ijantimicag.2015.12.008 Zhang, 2016, Chronic hepatitis C virus infection: a review of current direct-acting antiviral treatment strategies, N Am J Med Sci (Boston), 9, 47 Asociación Española para el Estudio del Hígado. Guías AEEH/SEIMC de manejo de la Hepatitis C. 2016. Available from: http://aeeh.es/ [cited 26.08.16]. Alves EC, Filipe HM, Martins JC, Rodrigues J, Andreozzi V, Vandewalle B, et al. Impact of the universal drug coverage program to eradicate the burden of hepatitis C in Portugal. 25th Conference of the APASL. Tokyo, 22 February 2016. Association Francaise pour l’Etude du Foie (AFEF). Recommandations AFEF sur la prise en charge des hepatites virales C. Juin 2015. Available from: http://www.afef.asso.fr/ [cited 03.10.16]. Australian Government Department of health. Fourth National Hepatitis C Strategy 2014-2017. Available from: https://consultations.health.gov.au/ [cited 03.10.16]. Ministerio de Sanidad Servicios Sociales e Igualdad. Plan Estratégico para el Abordaje de la Hepatitis C [Internet]. Available from: http://www.msssi.gob.es [cited 21.05.16]. Younossi, 2016, Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden, Gastroenterology, 150, 1599, 10.1053/j.gastro.2016.02.039 Buti, 2015, Profiles and clinical management of hepatitis C patients in Spain: disHCovery study, Rev Esp Quimioter, 28, 145 López-Bastida, 2010, Spanish recommendations on economic evaluation of health technologies, Eur J Health Econ, 11, 513, 10.1007/s10198-010-0244-4 Andriulli, 2008, Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis, Aliment Pharmacol Ther, 28, 397, 10.1111/j.1365-2036.2008.03763.x Awad, 2010, Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials, Hepatology, 51, 1176, 10.1002/hep.23504 Bacon, 2011, Boceprevir for previously treated chronic HCV genotype 1 infection, N Engl J Med, 364, 1207, 10.1056/NEJMoa1009482 Fried, 2002, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection, N Engl J Med, 347, 975, 10.1056/NEJMoa020047 Jacobson, 2011, Telaprevir for previously untreated chronic hepatitis C virus infection, N Engl J Med, 364, 2405, 10.1056/NEJMoa1012912 Khuroo, 2004, Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4, Aliment Pharmacol Ther, 20, 931, 10.1111/j.1365-2036.2004.02208.x Poordad, 2011, Boceprevir for untreated chronic HCV genotype 1 infection, N Engl J Med, 364, 1195, 10.1056/NEJMoa1010494 Rumi, 2010, Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C, Gastroenterology, 138, 108, 10.1053/j.gastro.2009.08.071 Vierling, 2014, Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response, J Hepatol, 60, 748, 10.1016/j.jhep.2013.12.013 Zeuzem, 2011, Telaprevir for retreatment of HCV infection, N Engl J Med, 364, 2417, 10.1056/NEJMoa1013086 Afdhal, 2014, Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection, N Engl J Med, 370, 1483, 10.1056/NEJMoa1316366 Afdhal, 2014, Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection, N Engl J Med, 370, 1889, 10.1056/NEJMoa1402454 Alonso, 2017, Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort, J Viral Hepat, 24, 304, 10.1111/jvh.12648 Andreone, 2014, ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection, Gastroenterology, 147, 359, 10.1053/j.gastro.2014.04.045 Bourlière, 2015, Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: A randomised, double-blind, phase 2 trial (SIRIUS), Lancet Infect Dis, 15, 397, 10.1016/S1473-3099(15)70050-2 Buti, 2017, Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO), Aliment Pharmacol Ther, 45, 468, 10.1111/apt.13883 Tapper, 2017, Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: The Trio Health study, J Viral Hepat, 24, 22, 10.1111/jvh.12611 Doss, 2015, Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4, J Hepatol, 63, 581, 10.1016/j.jhep.2015.04.023 European Medicines Agency [Internet]. Sovaldi (Summary of Product Characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002798/WC500160597.pdf [cited 21.12.15]. Feld, 2014, Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin, N Engl J Med, 370, 1594, 10.1056/NEJMoa1315722 Feld, 2016, Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks, J Hepatol, 64, 301, 10.1016/j.jhep.2015.10.005 Ferenci, 2014, ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV, N Engl J Med, 370, 1983, 10.1056/NEJMoa1402338 Forns, 2014, Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial, Gastroenterology, 146, 1669, 10.1053/j.gastro.2014.02.051 Gane, 2015, Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection, Gastroenterology, 149, 1454, 10.1053/j.gastro.2015.07.063 Jacobson, 2013, Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options, N Engl J Med, 368, 1867, 10.1056/NEJMoa1214854 Jacobson, 2014, Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial, Lancet, 384, 403, 10.1016/S0140-6736(14)60494-3 Jensen DM, O’Leary JG, Pockros PJ, Sherman KE, Kwo PY, Mailliard ME, et al. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: Real-world experience in a diverse, longitudinal observational cohort. Hepatology 2014. The Liver Meeting, AASLD 6-11 Nov 2014. Oral 19. Kapoor R, Kohli A, Sidharthan S, Sims Z, Petersen T, Osinusi A, et al. Treatment of hepatitis C genotype 4 with ledipasvir and sofosbuvir for 12 weeks: Results of the SYNERGY Trial. 65th Annual Meeting of the American Association for the Study of Liver Diseases; 2014 Nov 7-11. Boston, MA, 2014. Kowdley, 2014, Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis, N Engl J Med, 370, 1879, 10.1056/NEJMoa1402355 Kwo, 2016, Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study, Hepatology, 64, 370, 10.1002/hep.28467 Lawitz, 2013, Sofosbuvir for previously untreated chronic hepatitis C infection, N Engl J Med, 368, 1878, 10.1056/NEJMoa1214853 Lawitz, 2014, Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naïve patients: the COSMOS randomised study, Lancet, 384, 1756, 10.1016/S0140-6736(14)61036-9 Lawitz, 2015, Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis, Hepatology, 61, 769, 10.1002/hep.27567 Lawitz, 2016, Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2), Hepatology, 64, 360, 10.1002/hep.28422 Leroy, 2016, Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+), Hepatology, 63, 1430, 10.1002/hep.28473 Manns, 2014, Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): A randomised, double-blind, placebo-controlled phase 3 trial, Lancet, 384, 414, 10.1016/S0140-6736(14)60538-9 Moreno, 2015, Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4, J Hepatol, 62, 1047, 10.1016/j.jhep.2014.12.031 Poordad, 2014, ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis, N Engl J Med, 370, 1973, 10.1056/NEJMoa1402869 Reddy, 2015, Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis, Hepatology, 62, 79, 10.1002/hep.27826 Sulkowski, 2014, Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection, N Engl J Med, 370, 211, 10.1056/NEJMoa1306218 Waked, 2016, Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): A multicentre, phase 3, partly randomised open-label trial, Lancet Gastroenterol Hepatol, 1, 36, 10.1016/S2468-1253(16)30002-4 Zeuzem, 2014, Sofosbuvir and ribavirin in HCV genotypes 2 and 3, N Engl J Med, 370, 1993, 10.1056/NEJMoa1316145 Zeuzem, 2014, Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin, N Engl J Med, 370, 1604, 10.1056/NEJMoa1401561 Spanish Ministry of Health, Social Policy and Equality. Institute for Health Information. Press releases, 2016 [Internet]. Available from: http://www.msssi.gob.es/gabinete/notasPrensa.do?id=3909 [cited 23.02.16]. European Association for the Study Liver (EASL). Recommendations on treatment of hepatitis C 2015. Clinical practice guidelines. Available from: http://www.easl.eu/. Published 2015 [cited 21.12.15]. IPSOS HCV MONITOR Spain, Q4 2014 Report. Buti, 2005, Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C, J Hepatol, 42, 639, 10.1016/j.jhep.2004.12.031 Chahal, 2016, Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population, JAMA Intern Med, 176, 65, 10.1001/jamainternmed.2015.6011 Ferrante, 2013, Boceprevir for previously untreated patients with chronic hepatitis C genotype 1 infection: a US-based cost-effectiveness modeling study, BMC Infect Dis, 13, 190, 10.1186/1471-2334-13-190 Maylin, 2008, Eradication of hepatitis C virus in patients success fully treated for chronic hepatitis C, Gastroenterology, 135, 8219, 10.1053/j.gastro.2008.05.044 Saab, 2010, Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model, Liver Transpl, 16, 748 San Miguel, 2015, Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C, Gut, 64, 1277, 10.1136/gutjnl-2014-307772 Younossi, 2015, Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection, Aliment Pharmacol Ther, 41, 544, 10.1111/apt.13081 Spanish Ministry of Health, Social Policy and Equality. Hepatic mortality by age in Spain. Available from: http://www.msssi.gob.es [cited 23.02.16]. Spanish Ministry of Health, Social Policy and Equality. Institute for Health Information. All-causes mortality in Spain. Available from: http://www.msssi.gob.es [cited 25.02.16]. Ministry of Finance and Public Administration. Update on the stability porgramm 2016-2019 [internet]. Available from: http://www.msssi.gob.es/ciudadanos/enfLesiones/enfTransmisibles/docs/plan_estrategico_hepatitis_C.pdf [cited 25.02.16]. Spanish General Council of Official Colleges of Pharmacists-Bot PLUS 2.0. Available from: https://botplusweb.portalfarma.com/ [cited 10.11.15]. Buti, 2014, Cost-utility analysis of triple therapy with telaprevir in treatment-naïve hepatitis C patients, Farm Hosp, 38, 418 Townsend, 2011, Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C, Value Health, 14, 1068, 10.1016/j.jval.2011.06.006 Kieran, 2015, Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study, BMC Infect Dis, 15, 471, 10.1186/s12879-015-1208-1 Chhatwal, 2015, Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States, Ann Intern Med, 162, 397, 10.7326/M14-1336 Chhatwal, 2016, Direct-acting antiviral agents for patients with hepatitis C virus genotype 1 infection are cost saving, Clin Gastroenterol Hepatol, 16, 30673 Chhatwal, 2016, Systemic review of modelling approaches for the cost effectiveness of hepatitis C treatment with direct-acting antivirals, Pharmacoeconomics, 34, 551, 10.1007/s40273-015-0373-9 Gimeno-Ballester, 2016, Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients, Expert Rev Gastroenterol Hepatol, 11, 1 Gimeno-Ballester, 2016, Cost-effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C, Expert Rev Pharmacoecon Outcomes Res, 16, 285, 10.1586/14737167.2015.1081061 Saab, 2016, Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US, J Med Econ, 19, 795, 10.1080/13696998.2016.1176030 Calvaruso, 2016, Why do I treat my patients with mild hepatitis C?, Liver Int, 36, 7, 10.1111/liv.13011 Chidi, 2016, Economics and public health impacts of policies restricting access to hepatitis C treatment for Medicaid patients, Value Health, 19, 326, 10.1016/j.jval.2016.01.010 Deuffic-Burban, 2016, Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: The French case, J Viral Hepat, 23, 767, 10.1111/jvh.12546 Ramos, 2017, Interferon-free treatments in patients with hepatitis C genotype 1-4 infections in a real-world setting, World J Gastrointest Pharmacol Ther, 8, 137, 10.4292/wjgpt.v8.i2.137 Buti, 2016, Cost-effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis, Gastroenterol Hepatol, 39, 449, 10.1016/j.gastrohep.2016.03.006 Mar, 2016, Análisis coste-efectividad del tratamiento de la hepatitis C crónica con sofosbuvir-simeprevir en pacientes con genotipo 1 y fibrosis avanzada, Med Clin (Barc), 146, 61, 10.1016/j.medcli.2015.09.019 Marcellusi, 2016, Early treatment in HCV: Is it a cost-utility option from the Italian perspective?, Clin Drug Investig, 36, 661, 10.1007/s40261-016-0414-y Adinolfi, 2015, All-oral interferon-free treatments: the end of hepatitis C virus story, the dream and the reality, World J Hepatol, 7, 2363, 10.4254/wjh.v7.i22.2363 Van Nuys, 2015, Broad hepatitis C treatment scenarios return substantial health gains but capacity is a concern, Health Aff (Millwood), 34, 1666, 10.1377/hlthaff.2014.1193 McHutchison, 2009, Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection, N Engl J Med, 360, 1827, 10.1056/NEJMoa0806104 McHutchison, 2010, Telaprevir for previously treated chronic HCV infection, N Engl J Med, 362, 1292, 10.1056/NEJMoa0908014 Backx, 2014, The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy, J Viral Hepat, 21, 208, 10.1111/jvh.12132 Martin, 2016, Priorization of HCV treatment in the direct-acting antiviral era: an economic evaluation, J Hepatol, 65, 17, 10.1016/j.jhep.2016.02.007 Younossi, 2016, Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries, J. Viral Hepat, 23, 217, 10.1111/jvh.12483 Oliva-Moreno, 2015, Labour productivity losses caused by premature death associated with hepatitis C in Spain, Eur J Gastroenterol Hepatol, 27, 631, 10.1097/MEG.0000000000000336 Ampuero, 2016, Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options, World J Gastroenterol, 22, 5285, 10.3748/wjg.v22.i22.5285 Zhu, 2016, Systematic review and network meta-analysis of randomized controlled trials: Comparative effectiveness and safety of direct-acting antiviral agents for treatment-naïve hepatitis C genotype 1, Medicine (Baltimore), 95, e3004, 10.1097/MD.0000000000003004 Vallejo-Torres L, García-Lorenzo B, Castilla I, Valcárcel C, García-Pérez L, Linertová R, et al. Valor monetario de un año de vida ajustado por calidad: Estimación empírica del coste de oportunidad en el Sistema Nacional de Salud. Ministerio de Sanidad, Servicios Sociales e Igualdad. Servicio de Evaluación del Servicio Canario de la Salud; 2015. Informes de Evaluación de Tecnologías Sanitarias. Available from: http://www3.gobiernodecanarias.org/ [accessed 25.02.16]. Sacristán, 2002, ¿Qué es una tecnología sanitaria eficiente en España?, Gac. Sanit, 16, 334, 10.1016/S0213-9111(02)71933-X